PARSIPPANY, N.J., July 05, 2023--Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 23 newly-hired, non-executive employees.
Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy.
Japan's Astellas Pharma said on Monday it agreed to buy U.S.-based drugmaker IVERIC Bio Inc for about $5.9 billion in its biggest acquisition, giving it access to a range of ophthalmology treatments. Through Berry Merger Sub Inc, a wholly-owned subsidiary of Astellas U.S. Holding, the Japanese company agreed to acquire IVERIC for $40 per share in cash, Astellas said in a release. The acquisition price is a 22% premium to IVERIC's $32.89 closing price on April 28.